This paper is only available as a PDF. To read, Please Download here.
Visceral hypersensitivity (VH) is commonly cited as a major driver of chronic abdominal
pain in “functional” gastrointestinal disorders (e.g., irritable bowel syndrome) where
persistent and/or recurrent abdominal pain is the primary unifying symptom regardless
of any alterations in bowel habits. The complexity of VH is in part influenced by
genetic factors and individual differences in gut microbiome composition, yet specific
mechanisms that generate VH remain incompletely understood. Correspondingly, current
treatments to primarily focus on symptom management rather than targeting physiological
mechanisms responsible for generating VH. We have begun to examine the role of genetic
susceptibility and microbiome response dynamics in VH development using a preclinical
model of intracolonic zymosan (ZYM) administration in which there are strain differences
to VH susceptibility. Preliminary data reveals differential susceptibility between
ZYM-induced VH in two closely related C57BL/6 sub strains, one from Taconic Biosciences
(C57BL/6NTac) and the other from Jackson Laboratory (C57BL/6J). We have identified
a VH candidate gene that encodes the arginine-vasopressin receptor 1A (AVPR1A) protein.
We have further observed dynamic strain differences in the location and composition
of the gut microbiome in response to ZYM corresponding to VH susceptibility. Ongoing
studies are focused on teasing apart the potential bidirectional relationship(s) between
genetic susceptibility and host-microbiome interactions in the etiology of VH. Identifying
underlying mechanisms that drive VH would provide novel targets for pharmacological
intervention and decrease reliance on opioids, which are prescribed at a significantly
higher rate to patients who report abdominal pain with no accompanying structural
disease. Grant support from R21 NS104789/NS/NINDS (KMB), R03 NS096454/NS/NINDS (KMB),
Rita Allen Foundation Award in Pain (KMB), P20GM103418 (EEY and KMB), and a K-INBRE
recruitment startup package.
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to The Journal of PainAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
Article info
Identification
Copyright
© 2022 Published by Elsevier Inc.